Abstract: A formulation for topical administration of timolol maleate is disclosed. The formulation, when administered at a daily dose from about 0.4 to about 15 mg/cm2/day, provides a steady state mean timolol blood Cmax,ss below 3 ng/ml in a subject in need thereof, wherein at steady state the ratio of Cmax,SS/Cmin,SS is less than 2. Also disclosed herein is a method of treating skin conditions such as infantile hemangiomas and chronic venous leg ulcer.

Abstract: Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Abstract: The present invention provides a pharmaceutical composition of diltiazem hydrochloride. The pharmaceutical composition is preferably a gel and comprises diltiazem hydrochloride and excipients including propylene glycol, benzoic acid, and a gel matrix, which comprises one or both of povidone and hydroxypropyl cellulose. Based on percentage by weight, the diltiazem hydrochloride accounts for 1%-5%, the gel matrix accounts for 5%-10%, with pH maintained at 3.0-4.5. A preparation method is provided accordingly, with simple and readily available raw materials and stable quality.

Abstract: Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Abstract: The present invention provides a pharmaceutical composition of diltiazem hydrochloride. The pharmaceutical composition is preferably a gel and consists of diltiazem hydrochloride and excipients including propylene glycol, benzoic acid, and a gel matrix, which is one of or a mixture of povidone and hydroxypropyl cellulose. Based on percentage by weight, the diltiazem hydrochloride accounts for 1%-5%, the benzoic acid accounts for 0.1%-5.0%, the gel matrix accounts for 5%-10%, and the balance is propylene glycol, with pH maintained at 3.0-4.5. A preparation method is provided accordingly, with simple and readily available raw materials and stable quality.

Abstract: The present invention presents an automatic compounding machine for food and medicine and relates to the technical field of food and medicine preparation. An automatic compounding machine for food and medicine, including a hatch, the hatch is provided with an automatic powder dropping module for feeding special powder, an automatic water filling module for feeding water, and a bottle holder for supporting a mixing bottle; the bottle holder is provided with a first drive motor, and the drive shaft of the first drive motor is provided with a first mounting plate, and the first mounting plate is provided with two magnetic blocks at intervals. The present invention can be used for mixing and stirring the contents of solid food, tablets or capsules with special powders and pure water into a liquid suspension, thus facilitating the taking of solid food or drugs, and the accurate dosing division of drugs, saving time and effort with high preparation efficiency.

Abstract: The present invention presents an automatic compounding machine for food and medicine and relates to the technical field of food and medicine preparation. An automatic compounding machine for food and medicine, including a hatch, the hatch is provided with an automatic powder dropping module for feeding special powder, an automatic water filling module for feeding water, and a bottle holder for supporting a mixing bottle; the bottle holder is provided with a first drive motor, and the drive shaft of the first drive motor is provided with a first mounting plate, and the first mounting plate is provided with two magnetic blocks at intervals. The present invention can be used for mixing and stirring the contents of solid food, tablets or capsules with special powders and pure water into a liquid suspension, thus facilitating the taking of solid food or drugs, and the accurate dosing division of drugs, saving time and effort with high preparation efficiency.

Abstract: The present invention provides a pharmaceutical composition of diltiazem hydrochloride. The pharmaceutical composition is preferably a gel and consists of diltiazem hydrochloride and excipients including propylene glycol, benzoic acid, and a gel matrix, which is one of or a mixture of povidone and hydroxypropyl cellulose. Based on percentage by weight, the diltiazem hydrochloride accounts for 1%-5%, the benzoic acid accounts for 0.1%-5.0%, the gel matrix accounts for 5%-10%, and the balance is propylene glycol, with pH maintained at 3.0-4.5. A preparation method is provided accordingly, with simple and readily available raw materials and stable quality.

Abstract: Disclosed herein is a fast-dispersing suspending composition which promotes the formation of a suspension for pharmaceutical, food and veterinary products. The composition includes a suspending agent, a diluent, and a glidant, wherein the amounts of these agents are selected to enable the dispersion of the composition and the formation of the suspension. Also disclosed are a method of forming a suspension of a solid dosage form and a method of administering the resulting suspension to a subject.

Abstract: Disclosed herein is a fast-dispersing suspending composition which promotes the formation of a suspension for pharmaceutical, food and veterinary products. The composition includes a suspending agent, a diluent, and a glidant, wherein the amounts of these agents are selected to enable the dispersion of the composition and the formation of the suspension. Also disclosed are a method of forming a suspension of a solid dosage form and a method of administering the resulting suspension to a subject.

Abstract: A tablet for oral suspension formulation suitable for reconstitution is disclosed. The tablet contains a disintegrant, a wetting agent, a lubricant and other excipients in selected amounts to provide fast disintegration and dissolution in water. Also disclosed is a method of treating a disease by administering to a subject in need thereof a tablet disclosed herein.

Abstract: This document discloses a powder formulation of tadalafil for oral administration. Also disclosed are a method of preparing the powder formulation, a suspension dosage form of tadalafil and a method of treating diseases.

Abstract: This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.

Abstract: This document discloses a powder formulation of tadalafil for oral administration. Also disclosed are a method of preparing the powder formulation, a suspension dosage form of tadalafil and a method of treating diseases.

Abstract: This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.

Abstract: Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Abstract: This document discloses a sustained release dosage form for oral administration of entecavir in a subject. Also disclosed is a method of treating hepatitis virus B infection.

Abstract: This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.

Abstract: Soluble pharmaceutical compositions of nilotinib or a pharmaceutically acceptable salt thereof were invented using one or more organic acids that function as a solubilizing agent, increasing the bioavailability of nilotinib and supressing the food effect associated with certain compositions of nilotinib. The pharmaceutical compositions are in the form of solid oral dosage forms, including capsules and tablets.